Basit öğe kaydını göster

Clinical significance of serum Protease-Activated Receptor-1 (PAR-1) levels in patients with cutaneous melanoma

dc.contributor.authorBilgin, Elif
dc.contributor.authorDuranyildiz, Derya
dc.contributor.authorTas, Faruk
dc.contributor.authorKarabulut, Senem
dc.contributor.authorErturk, Kayhan
dc.date.accessioned2021-03-03T14:07:04Z
dc.date.available2021-03-03T14:07:04Z
dc.identifier.citationTas F., Bilgin E., Karabulut S., Erturk K., Duranyildiz D., "Clinical significance of serum Protease-Activated Receptor-1 (PAR-1) levels in patients with cutaneous melanoma", BBA CLINICAL, cilt.5, ss.166-169, 2016
dc.identifier.othervv_1032021
dc.identifier.otherav_37d57f66-22de-442d-8d81-62f4777ee9da
dc.identifier.urihttp://hdl.handle.net/20.500.12627/41639
dc.identifier.urihttps://doi.org/10.1016/j.bbacli.2016.04.001
dc.description.abstractBackground: Protease-Activated Receptor-1 (PAR-1) plays an important role in the pathogenesis of multiple malignancies and its expression strongly also affects the outcomes of cancer patients. The objective of this study was to determine the clinical significance of the serum levels of PAR-1in cutaneous melanoma patients.
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectTIP, GENEL & İÇECEK
dc.titleClinical significance of serum Protease-Activated Receptor-1 (PAR-1) levels in patients with cutaneous melanoma
dc.typeMakale
dc.relation.journalBBA CLINICAL
dc.contributor.departmentİstanbul Üniversitesi , Onkoloji Enstitüsü , Temel Onkoloji
dc.identifier.volume5
dc.identifier.startpage166
dc.identifier.endpage169
dc.contributor.firstauthorID232715


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster